Bausch Health Companies Inc Stock Price, News & Analysis

Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), will present 14 scientific posters on its ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting from July 23-27, 2021, in Las Vegas. These presentations cover key areas such as the clinical performance of IOL platforms and the impact of COVID-19 on surgeries. The event marks a significant return to in-person scientific exchanges, emphasizing the company's commitment to research and improved patient outcomes.

Bausch Health Companies (NYSE/TSX: BHC) announces the U.S. launch of Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes designed for dry, irritated eyes. These products are preservative-free, pH-balanced, and utilize naturally inspired ingredients to provide instant relief. They will be available at major retailers like Walgreens and CVS, with a suggested price starting at $11.99. This launch responds to an increasing need for eye care products in the context of rising digital device usage.

Bausch Health Companies (BHC) and Novaliq GmbH have completed enrollment for the second Phase 3 study (MOJAVE) of the investigational drug NOV03, aimed at treating dry eye disease due to meibomian gland dysfunction, involving 622 participants. The drug, if approved, could become a first-in-class treatment. A New Drug Application is planned for submission to the FDA in 2022. Previous Phase 3 trials showed statistically significant results, and ongoing studies aim to reaffirm these findings.

Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter 2021 financial results on August 3, 2021. A conference call and live web cast will be held at 8:00 a.m. EDT to discuss these results, along with a business update. All relevant materials will be available on the company's Investor Relations webpage before the call. Bausch Health focuses on improving lives through its pharmaceutical, medical device, and over-the-counter products primarily in eye health, gastroenterology, and dermatology.

Bausch Health Companies (NYSE/TSX: BHC) announced a significant debt reduction of $150 million by redeeming its 6.125% Senior Notes due in 2025. This redemption, effective August 2, 2021, will bring the total debt redeemed in 2021 to $650 million, utilizing cash generated from operations. The company aims to strengthen its balance sheet and enhance financial flexibility. Bausch Health is committed to advancing healthcare through its diverse range of pharmaceutical products.

Bausch + Lomb, a unit of Bausch Health Companies (NYSE: BHC), announced the U.S. launch of expanded parameters for the Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses. The addition of -2.25D and -2.75D cylinder power increases options for the 32 million people in the U.S. with both astigmatism and presbyopia. This enhancement aims to address the challenges eye care professionals face when fitting these patients, promising improved comfort and visual clarity.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has extended the expiration date for its cash tender offer to purchase all outstanding 7.00% Senior Secured Notes due 2024 by one business day to June 22, 2021, due to the Juneteenth holiday. The Tender Offer commenced on May 24, 2021, and aims to facilitate the purchase of the Notes as outlined in the Offer to Purchase dated May 24, 2021. Goldman Sachs & Co. LLC is the dealer manager for this Tender Offer, providing assistance to holders of the Notes.

Bausch Health Companies (NYSE/TSX: BHC) announced the resignation of D. Robert Hale from its Board of Directors, effective June 21, 2021. Hale, a director since 2015, cited increased professional obligations, including joining the board of another company in Japan. CEO Joseph C. Papa expressed gratitude for Hale's contributions, emphasizing the company's commitment to executing the spinoff of Bausch + Lomb. The company aims to establish two strong boards with diverse representation to better serve stakeholders.

Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), announced an agreement with Lochan LLC to develop next-generation eyeTELLIGENCE™ software, aimed at enhancing efficiency in ophthalmic surgeries. Expected to launch in 2022, the software will integrate various surgical processes, reducing manual data transfers that lead to errors. This initiative follows Bausch + Lomb's 2018 introduction of eyeTELLIGENCE, designed to improve practice efficiency through cloud technology.